Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 512.6 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - fluconazole 2 mg/ml - solution for infusion - 0.2% w/v - active: fluconazole 2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole-claris can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - bupivacaine hydrochloride monohydrate 2.5 mg/ml - solution for injection - 0.25 % - active: bupivacaine hydrochloride monohydrate 2.5 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - surgical anaesthesia - epidural block for surgery

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - bupivacaine hydrochloride monohydrate 5 mg/ml - solution for injection - 0.5 % - active: bupivacaine hydrochloride monohydrate 5 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - surgical anaesthesia - epidural block for surgery

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - lidocaine hydrochloride monohydrate 10.66 mg/ml equivalent to lidocaine hydrochloride 10.0 mg/ml - solution for injection - 1% w/v - active: lidocaine hydrochloride monohydrate 10.66 mg/ml equivalent to lidocaine hydrochloride 10.0 mg/ml excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - lidocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: local infiltration; minor or major nerve blocks; epidural block; arthroscopy; intravenous regional anaesthesia.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - lidocaine hydrochloride monohydrate 21.32 mg/ml equivalent to lidocaine hydrochloride 20.0 mg/ml - solution for injection - 2% w/v - active: lidocaine hydrochloride monohydrate 21.32 mg/ml equivalent to lidocaine hydrochloride 20.0 mg/ml excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - indicated for the production of local or regional anaesthesia by the following techniques: local infiltration minor or major nerve blocks epidural block arthroscopy intravenous regional anaesthesia

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - flumazenil 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: flumazenil 0.1 mg/ml excipient: disodium edetate glacial acetic acid sodium chloride sodium hydroxide water for injection - for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia: -termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. -reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. -reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin: -for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. -as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. -flumazenil-claris may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).